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Breast: Is There a Common Origin? The Role of
Prolactin-induced Protein
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Abstract: Noninvasive breast lesions encompass a heterogeneous
group of risk indicators and nonobligate precursors of breast
cancer, such as apocrine hyperplasia (AH) and columnar cell
lesions (CCLs). Given the different expression of ER and ER-
regulated genes in AH and CCL, these 2 alterations are currently
considered discrete conditions. However, whether they share
early biologic changes is not clear to date. Here, we sought to
define the clinicopathologic and immunohistochemical features
of a prospective series of combined lesions made up by CCLs and
AH forming a continuum within single TDLUs. The study group
included 19 cases, whereas 25 cases of synchronous contiguous
CCLs and AH served as control group. The different compo-
nents of each case were subjected to immunohistochemical
analysis for ER, PR, AR, HER2, BCL2, CCND1, MUC1, and
PIP. Although CCLs and AHs arising in continuity showed
opposite patterns of ER expression, the PIP-positive apocrine
signature was consistently present in both components. In con-
clusion, apocrine changes are highly recurrent in CCLs growing
within foci of AH, regardless of the ER activation. Our results
suggest that PIP-positive and PIP-negative CCLs are likely to
represent biologically distinct conditions and that apocrine
changes might occur earlier than ER activation in the natural
history of breast precursor lesions.
Key Words: breast, fibrocystic changes, apocrine hyperplasia,
columnar cell lesion, immunohistochemistry, PIP, GCDFP15
(Appl Immunohistochem Mol Morphol 2017;00:000–000)
Breast cancer risk indicators, precursors, and non-obligate precursors are part of a complex and heter-
ogeneous group of lesions, which represents a matter of
remarkable interest from both clinical and biological
standpoints.1 These frequent alterations of the breast
range from benign metaplastic changes to high-grade
ductal carcinoma in situ (DCIS) and are associated with
an increased probability of finding neighboring
malignancies.1,2 Their histologic subclassification is usu-
ally straightforward and morphology-based.3 However, in
a subset of cases, particularly in bioptic samples, the di-
agnosis might be challenging, given their tight dimensions
and overlapping morphologies.2,4,5
On the basis of the activation of the estrogen re-
ceptor (ER) and ER-regulated genes, a multistep model of
breast cancer evolution, encompassing most of the pre-
cursors and nonobligate precursors of breast cancer, has
been proposed.1 To date, high-throughput sequencing
studies are validating this hypothesis.5–8 Regrettably, the
individual risk assessment of breast noninvasive lesions is
far from being achieved. Among all, subclassification of
columnar cell lesions (CCLs) is particularly challenging.9
The alterations belonging to this group are morphologi-
cally characterized by dilated acinar structures lined by a
single layer of ER-positive, HER2-negative bland col-
umnar cells with apical snouts, showing different degrees
of cytological atypia.3,9,10 Molecular studies showed that
the majority of CCLs, together with atypical ductal hy-
perplasia (ADH) and low-grade DCIS, are clonal and
nonobligate precursors of invasive breast cancer, belong-
ing to the so-called “low-grade breast neoplasia family.”2
CCLs are often seen in association with a wide spectrum
of other breast alterations, including apocrine hyperplasia
(AH).10 This common condition is histologically defined
by the presence of cells with abundant eosinophilic cyto-
plasm, containing small, glycolipid granules, and large
round-to-oval monomorphic nuclei with prominent
nucleoli.7,11 AH immunophenotype shows substantial
differences compared with CCLs, given the lack of ER
expression and the diffuse expression of the prolactin-in-
duced protein (PIP), also known as gross cystic disease
fluid protein 15.7,12,13 At present, the role of apocrine
changes in breast cancer tumorigenesis is a subject of de-
bate among pathologists, with several observational and
genetic studies suggesting that AH is a bona fide risk in-
dicator for breast cancer development.1 Furthermore,
based on the identification of allelic alterations in apocrine
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lesions, it has recently been hypothesized that at least a
subset of them are clonal.7
Although CCLs and AH display distinct repertoires
of morphologic, immunophenotypic, and molecular fea-
tures, their coexistence is frequently observed.3,14 How-
ever, the biologic relationship between these 2 lesions has
yet to be elucidated. The aim of the current study was to
define the clinicopathologic and immunohistochemical
features of a prospective series of combined lesions made
up by CCLs and AH arising in continuity within single
terminal duct-lobular units (TDLUs).
MATERIALS AND METHODS
Patients and Tissue Specimens
Nineteen cases of breast fibrocystic changes made up
by CCLs forming a continuum with AH inside of the same
TDLU were included in this study. Specifically, 17 cases
were prospectively collected between January 2015 and
May 2016 in the Division of Pathology, Fondazione
IRCCS Ca’ Granda—Ospedale Maggiore Policlinico,
Milan, Italy, whereas 2 additional surgical samples were
retrieved from our institutional database. Follow-up time
ranged from 13 to 58 months. As a control group, 25
breast bioptic or surgical samples in which both CCLs and
AH coexisted in contiguity but not in continuity were
retrospectively retrieved. Clinical and follow-up data were
recorded for all patients. The samples were anonymized
before analysis, and the study was fully compliant with the
local ethical guidelines. All cases were reviewed in-
dependently by 2 breast pathologists (L.R. and N.F.) and
classified according to standard criteria.2,3
Immunohistochemistry
Representative 4 μm-thick sections of all cases were
subjected to immunohistochemical analyses using pre-
diluted antibodies against ER, PR, androgen receptor
(AR), HER2, B-cell lymphoma 2 (Bcl2), cyclin D1
(CCND1), MUC1, and PIP. For each case, the expression
of all markers was evaluated separately in the morpho-
logically distinct components. Briefly, the protocol uses
the Dako automated staining platform (Dako Omnis) and
antihuman prediluted antibodies.15,16 Protein expression
was analyzed separately in the discrete components.
The methods and scoring systems employed followed
previously reported criteria17–21 and guidelines,22,23 as
detailed in Table 1.
RESULTS
All patients included in the study group except one
were female (18/19, 94%), with a mean age at diagnosis of
53 years (range, 32 to 72). Bioptic procedures, either core or
vacuum-assisted biopsy, were performed in 17 of 19 (89%)
cases, whereas in the remaining 2 cases the tissue was ob-
tained after surgical excision. All cases showed foci of fi-
brocystic changes in which a single TDLU displayed the
abnormal presence of single-layered, pseudostratified bland
columnar cells with apical snouts, and an adjacent hyper-
plastic proliferation of eosinophilic cells with abundant
cytoplasm, monomorphic nuclei, containing glycolipid
granules, consistent with a CCLs growing within foci of
AHs (Fig. 1). Adjacent breast carcinoma of no special type
was present only in the 2 surgically resected specimens and
in 1 bioptic specimen (3/19, 16%). Interestingly, only 1
patient developed an invasive carcinoma during the follow-
up time. In this case, CCLs and AH were associated with
LCIS at the time of diagnosis. Other patients without
carcinoma at the diagnosis presented an indolent behavior.
Clinicopathologic features of the study group are detailed
in Table 2.
At immunohistochemical analysis, as expected,
CCLs showed a diffuse ER, PR, BCL2, expression, while
lacking AR, HER2, CCND1, and MUC1. Conversely, the
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TABLE 1. List of Antibodies, Clones, Dilutions, Antigen Retrieval Methods, and Scoring Systems Adopted for Immunohistochemical
Analyses
Marker Clone Dilution Antigen Retrieval Company Scoring
ER EP1 RTU EnVision FLEX, high pH, 200 Dako ASCO/CAP guidelines; positive if ≥ 1% of
tumor cell nuclei are immunoreactive22
PR PgR 636 1:100 EnVision FLEX, high pH, 300 Dako ASCO/CAP guidelines; positive if ≥ 1% of
tumor cell nuclei are immunoreactive22
AR AR441 1:50 EnVision FLEX, high pH, 200 Dako Positive if ≥ 1% cells showed a faint to
strong nuclear staining17
HER2 Polyclonal 1:400 EnVision FLEX, low pH, 300 Dako ASCO/CAP guidelines; positive if ≥ 1%
complete, intense circumferential
membrane staining23
Bcl2 124 RTU EnVision FLEX, high pH, 300 Dako Positive if ≥ 1% cells showed strong
nuclear staining18
Cyclin D1 EP12 RTU EnVision FLEX, high pH, 300 Dako Semiquantitative scoring according to the
Allred method19
MUC1 E29 RTU EnVision FLEX, high pH, 300 Dako Positive if ≥ 1% showed any cytoplasmic
staining20
PIP 23A3 RTU EnVision FLEX, high pH, 300 Dako Positive if cells showed strong and diffuse
cytoplasmic staining21
AR indicates androgen receptor; Bcl2, B-cell lymphoma 2; ER, estrogen receptor alpha; MUC1, mucin 1 cell surface associated (aka EMA, epithelial membrane
antigen); PIP, prolactin-inducible protein (aka GCDFP15, gross cystic disease fluid protein 15); PR, progesterone receptor; RTU, ready to use.
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areas of AH showed diffuse AR, CCND1, and MUC1
expression, while lacking ER, PR, and BCL2 expression.
Intriguingly, despite these well-known divergent im-
munoprofiles, both components showed strong and diffuse
PIP overexpression in 100% of the cases belonging to the
study group (Fig. 1). Among the control group, only the AH
showed a PIP-positive apocrine immunoprofile, whereas the
contiguous CCL was consistently PIP-negative (Fig. 2). The
results of the immunohistochemical analysis are summarized
in Table 3.
DISCUSSION
In this study, we have characterized at morphologic
and immunohistochemical levels a consecutive series of
CCLs forming a continuum with foci of typical AH in the
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FIGURE 1. Representative micrographs of a columnar cell lesion and associated apocrine hyperplasia involving the same terminal
duct. In this case, the columnar cell lesion (arrowheads) formed a continuum with a focus apocrine hyperplasia (stars) (A,
hematoxylin and eosin, original magnification ×50) in the context of fibrocystic changes (lower part of the micrograph). At higher
magnification (B, hematoxylin and eosin, original magnification ×200), the so-called “hybrid cells” were observed in the transition
area between the 2 components, bearing intermediate cytological features, as shown in the inset (hematoxylin and eosin, original
magnification ×400). The columnar cell lesion displayed ER (C) and PR (D) coexpression, whereas the adjacent apocrine hyper-
plasia showed strong positivity for AR (E) and cyclin D1 (F). Intriguingly, both the columnar cell lesion and apocrine hyperplasia
shared an apocrine immunophenotype, as demonstrated by the strong and diffuse PIP overexpression in both components (G).
The intact layer of myoepithelial cells surrounding the duct was highlighted by expression of p63 (H). ER indicates estrogen
receptor; PR, progesterone receptor; AR, androgen receptor; PIP, prolactin-induced peptide.
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TABLE 2. Clinicopathologic Features of 19 Columnar Cell Lesions Forming a Continuum With Apocrine Hyperplasia
Case Age Sex Location Specimen Microcalcifications Associated Lesions
EUSOMA Pathological
Classification Follow-up (mo)
CCLAH 1 47 Female UOQ, right
breast
Core biopsy Yes Fibrocystic changes B2 NED (29)
CCLAH 2 56 Female UIQ, right
breast
Core biopsy Yes Fibrocystic changes B2 NED (22)
CCLAH 3 72 Female LOQ, right
breast
Core biopsy, VAB Yes Fibrocystic changes, ADH B3 Low grade DCIS and fibrocystic changes at
VAB (1); NED (21)
CCLAH 4 72 Female UOQ, left
breast
VAB Yes Fibrocystic changes B2 NED (20)
CCLAH 5 62 Female UOQ, right
breast
Core biopsy Yes Fibrocystic changes, FEA B3 NED (20)
CCLAH 6 58 Female LIQ, right
breast
Core biopsy Yes Fibrocystic changes B2 NED (19)
CCLAH 7 70 Female UOQ, right
breast
Core biopsy No Fibrocystic changes, UDH B2 NED (18)
CCLAH 8 53 Female UOQ, left
breast
Core biopsy Yes Fibrocystic changes B2 FEA at core biopsy (12); FEA at core biopsy
(1); FEA and fibrocystic changes at VAB (1);
NED (17)
CCLAH 9 57 Female UOQ, right
breast
VAB Yes Fibrocystic changes, classic
LCIS
B3 NED (3), NED (3), ILC (17)
CCLAH 10 59 Female UOQ, right
breast
VAB Yes Fibrocystic changes B2 NED (16)
CCLAH 11 32 Male LOQ, left
breast
Core biopsy No Fibrocystic changes B2 NED (16)
CCLAH 12 40 Female UIQ, right
breast
Core biopsy Yes Fibrocystic changes, FEA B3 NED (1), NED (7), NED (15)
CCLAH 13 66 Female UOQ, right
breast
Core biopsy Yes Fibrocystic changes B2 NED (14)
CCLAH 14 41 Female LOQ, right
breast
VAB Yes Fibrocystic changes, IC NST
with apocrine differentiation
B5 Recurrence of IC NST (8)
CCLAH 15 53 Female LIQ, right
breast
Core biopsy No Fibrocystic changes B2 NED (14)
CCLAH 16 44 Female UOQ, right
breast
Core biopsy Yes Fibrocystic changes B2 NED (14)
CCLAH 17 39 Female UOQ, left
breast
Core biopsy Yes Fibrocystic changes B2 NED (13)
BR_134 50 Female UOQ, right
breast
Quadrantectomy No Fibrocystic changes, IC NST n/a NED (58)
BR_205 47 Female UOQ, right
breast
Quadrantectomy Yes Fibrocystic changes, IC NST n/a NED (42)
ADH indicates atypical ductal hyperplasia; FEA, flat epithelial atypia; IC NST, invasive carcinoma of no special type; ILC, invasive lobular carcinoma; LIQ, lower-internal quadrant; LOQ, lower-outer quadrant; n/a,
not applicable; NED no evidence of disease; UIQ, upper-internal quadrant; UOQ, upper-outer quadrant; VAB, vacuum-assisted biopsy.
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context of the same TDLU and demonstrated that the
apocrine immunophenotype is shared by the 2 contiguous
components, regardless of their ER activation status.
The unprecedented comprehension that ER-positive
and ER-negative lesions of the breast are clinically
discrete conditions has designated the road to precision
medicine in breast cancer patients.1 However, based on the
possible coexistence of these lesions, particularly at very early
tumorigenic phases,9,14,24 pathologists and oncologists are
now expected to define the clinical implications of the in-
terplay between AH and CCLs as risk indicators and pre-
cursors of breast cancer. In this era of precision medicine,
novel biomarkers that are able to predict the outcome related
to noninvasive and preinvasive lesions at an individualized
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FIGURE 2. Representative micrographs of fibrocystic changes in which columnar cell lesion and apocrine hyperplasia are present in
proximity but not in continuity. In this case, belonging to the control group, both columnar cell lesion (arrowheads) and apocrine
hyperplasia (stars) were present within the same area of fibrocystic changes (A, hematoxylin and eosin, original magnification
×100) with associated numerous microcalcifications (upper right corner of the micrograph). The 2 lesions did not display any
feature of morphologic conglomeration and PIP (B) and ER (C) proteins showed the characteristic patterns of expression of
columnar cell changes and apocrine hyperplasia, respectively, in which the former is PIP-negative and ER-positive, whereas the
latter is PIP-positive and ER-negative. ER indicates estrogen receptor; PIP, prolactin-induced peptide.
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level are warranted. In this respect, PIP (also known as
gross cystic disease fluid protein 15, GCDFP15) is a marker
of apocrine differentiation belonging to a family of glyco-
proteins that has been originally identified in the fluid
of breast cysts of perimenopausal women.25,26 This 17-kDa
single protein is ubiquitously present in apocrine, lacrimal,
salivary, ceruminous, Moll’s, and eccrine glands but also
in apocrine breast ductal cells and the so-called apocrine
metaplasia.26,27 Importantly, PIP is a well-known breast
cancer associated polypeptide, given its overexpression in the
majority of breast tumors.28 It has a significant function in
the biology of breast alterations, being involved in the me-
diation of cell invasion and regulation of signaling, partic-
ularly in ER-negative cases.29,30 Antibodies against PIP have
been shown to represent a useful tool for classifying breast
carcinoma and its metastatic deposits.27,31–33 It is of note,
however, that this protein shows intratumor heterogeneous
expression in the vast majority of breast cancers.32 Our
results showing that PIP overexpression can be irrespective
of ER activation in the context of fibrocystic changes
corroborate the notion that this protein is likely to play a key
role in the multistep evolution of breast cancer, as previously
hypothesized.7,34,35
Given that breast cancer cells have been shown to re-
lease PIP through increased androgen and prolactin levels,
and that high estrogen levels are able to inhibit its release,
this protein has been proposed as a biomarker to predict the
nature of breast tumors.28,32 The burgeoning interest in the
multitude of noninvasive breast abnormalities may reflect
their improved recognition by pathologists in everyday
practice and the progress that are currently being made in
the use of high-throughput sequencing methods. However,
the risk assessment of each nonmalignant lesion has by
no means fully clarified.4,5,9,14,36,37 In particular, apocrine
metaplasia and AH represent 2 distinct types of alterations
within the fibrocystic changes spectrum and almost
invariably display strong and diffuse PIP expression.14,25 The
role of this polypeptide, however, has never been explored in
associated CCLs. Recurrent allelic imbalances and copy
number alterations, as well as recurrent alterations in the
epidermal growth factor receptor family genes, have been
reported in CCLs and associated lesions, leading to the no-
tion that these entities are likely to represent the earliest
histologically detectable nonobligate precursors of low-grade
breast cancer.9,37 Despite CCLs and AH are currently con-
sidered biologically discrete conditions harboring distinct
repertoires of molecular alterations, our results suggest that,
under certain circumstances, they may exist along the same
neoplastic spectrum, and not only as a mere association, as
documented by the strong and diffuse immunohistochemical
overexpression of PIP in both components.
In conclusion, the results of the current study pro-
vide novel insights in the subclassification of nonobligate
precursors of breast cancers, where PIP-positive and PIP-
negative CCLs can represent histologically distinct con-
ditions. Our observations suggest that apocrine changes
may constitute an early phenotypic connection between
ER-positive and ER-negative noninvasive breast lesions.
Whether apocrine changes could represent the trigger of a
subset of ER-positive neoplastic processes, remains to be
elucidated. In this respect, wide molecular studies are
warranted to perform analyses on a large scale of non-
malignant lesions and their possible combinations. This
would provide the substrate for broadening our under-
standing of risk indicators and nonobligate precursors
to breast cancer, their biology, and the role of apocrine
lesions in breast cancer tumorigenesis.
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